173 related articles for article (PubMed ID: 36404323)
1. Validation of the revised diagnostic criteria for primary plasma cell leukemia by the Korean Multiple Myeloma Working Party.
Jung SH; Kim K; Yoon SE; Moon JH; Kim D; Kim HJ; Kim MK; Kim KH; Lee HJ; Lee JH; Kim SH; Yoo KH; Lee JH; Lee JJ
Blood Cancer J; 2022 Nov; 12(11):157. PubMed ID: 36404323
[TBL] [Abstract][Full Text] [Related]
2. Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma.
Ravi P; Kumar SK; Roeker L; Gonsalves W; Buadi F; Lacy MQ; Go RS; Dispenzieri A; Kapoor P; Lust JA; Dingli D; Lin Y; Russell SJ; Leung N; Gertz MA; Kyle RA; Bergsagel PL; Rajkumar SV
Blood Cancer J; 2018 Nov; 8(12):116. PubMed ID: 30442928
[TBL] [Abstract][Full Text] [Related]
3. Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients.
An G; Qin X; Acharya C; Xu Y; Deng S; Shi L; Zang M; Sui W; Yi S; Li Z; Hao M; Feng X; Jin F; Zou D; Qi J; Zhao Y; Tai YT; Wang J; Qiu L
Ann Hematol; 2015 Feb; 94(2):257-64. PubMed ID: 25231928
[TBL] [Abstract][Full Text] [Related]
4. Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.
Cowan AJ; Stevenson PA; Libby EN; Becker PS; Coffey DG; Green DJ; Hyun TS; Fromm JR; Gopal AK; Holmberg LA
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1386-1391. PubMed ID: 29481870
[TBL] [Abstract][Full Text] [Related]
5. Detection of circulating normal and tumor plasma cells in newly diagnosed patients of multiple myeloma and their associations with clinical and laboratory parameters.
Gupta L; Suku P; Dash A; Bose P; Sharma P; Mallik N; Sreedharanunni S; Varma N; Jandial A; Malhotra P; Sachdeva MUS
Curr Probl Cancer; 2024 Feb; 48():101025. PubMed ID: 37951052
[TBL] [Abstract][Full Text] [Related]
6. The detection of circulating plasma cells may improve the Revised International Staging System (R-ISS) risk stratification of patients with newly diagnosed multiple myeloma.
Galieni P; Travaglini F; Vagnoni D; Ruggieri M; Caraffa P; Bigazzi C; Falcioni S; Picardi P; Mazzotta S; Troiani E; Dalsass A; Mestichelli F; Angelini M; Camaioni E; Maravalle D; Angelini S; Pezzoni V
Br J Haematol; 2021 May; 193(3):542-550. PubMed ID: 33792026
[TBL] [Abstract][Full Text] [Related]
7. Comparison of outcomes after autologous stem cell transplantation between myeloma patients with skeletal and soft tissue plasmacytoma.
Shin HJ; Kim K; Lee JW; Song MK; Lee JJ; Lee HS; Lee WS; Kim SJ; Chung JS
Eur J Haematol; 2014 Nov; 93(5):414-21. PubMed ID: 24813053
[TBL] [Abstract][Full Text] [Related]
8. Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register.
Nahi H; Genell A; Wålinder G; Uttervall K; Juliusson G; Karin F; Hansson M; Svensson R; Linder O; Carlson K; Björkstrand B; Kristinsson SY; Mellqvist UH; Blimark C; Turesson I
Eur J Haematol; 2017 Sep; 99(3):216-222. PubMed ID: 28544116
[TBL] [Abstract][Full Text] [Related]
9. Plasma cell leukemia.
Albarracin F; Fonseca R
Blood Rev; 2011 May; 25(3):107-12. PubMed ID: 21295388
[TBL] [Abstract][Full Text] [Related]
10. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage.
Fernández de Larrea C; Kyle R; Rosiñol L; Paiva B; Engelhardt M; Usmani S; Caers J; Gonsalves W; Schjesvold F; Merlini G; Lentzch S; Ocio E; Garderet L; Moreau P; Sonneveld P; Badros A; Gahrton G; Goldschmidt H; Tuchman S; Einsele H; Durie B; Wirk B; Musto P; Hayden P; Kaiser M; Miguel JS; Bladé J; Rajkumar SV; Mateos MV
Blood Cancer J; 2021 Dec; 11(12):192. PubMed ID: 34857730
[TBL] [Abstract][Full Text] [Related]
11. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.
Fernández de Larrea C; Kyle RA; Durie BG; Ludwig H; Usmani S; Vesole DH; Hajek R; San Miguel JF; Sezer O; Sonneveld P; Kumar SK; Mahindra A; Comenzo R; Palumbo A; Mazumber A; Anderson KC; Richardson PG; Badros AZ; Caers J; Cavo M; LeLeu X; Dimopoulos MA; Chim CS; Schots R; Noeul A; Fantl D; Mellqvist UH; Landgren O; Chanan-Khan A; Moreau P; Fonseca R; Merlini G; Lahuerta JJ; Bladé J; Orlowski RZ; Shah JJ;
Leukemia; 2013 Apr; 27(4):780-91. PubMed ID: 23288300
[TBL] [Abstract][Full Text] [Related]
12. Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era.
Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
Blood Cancer J; 2016 Dec; 6(12):e512. PubMed ID: 27983726
[TBL] [Abstract][Full Text] [Related]
13. Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia.
Evans LA; Jevremovic D; Nandakumar B; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Hayman SR; Kapoor P; Leung N; Fonder A; Hobbs M; Hwa YL; Muchtar E; Warsame R; Kourelis TV; Go R; Russell S; Lust JA; Lin Y; Siddiqui M; Kyle RA; Gertz MA; Rajkumar SV; Kumar SK; Gonsalves WI
Am J Hematol; 2020 Jun; 95(6):637-642. PubMed ID: 32129510
[TBL] [Abstract][Full Text] [Related]
14. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.
Tabchi S; Nair R; Kunacheewa C; Patel KK; Lee HC; Thomas SK; Amini B; Ahmed S; Mehta RS; Bashir Q; Qazilbash MH; Weber DM; Orlowski RZ; Alexanian R; Feng L; Manasanch EE
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):560-569. PubMed ID: 31201134
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and Management of Multiple Myeloma: A Review.
Cowan AJ; Green DJ; Kwok M; Lee S; Coffey DG; Holmberg LA; Tuazon S; Gopal AK; Libby EN
JAMA; 2022 Feb; 327(5):464-477. PubMed ID: 35103762
[TBL] [Abstract][Full Text] [Related]
16. Clinical analysis of 40 multiple myeloma patients with extramedullary plasmacytoma of the head.
Sun WJ; Zhang JJ; An N; Shen M; Huang ZX; Li X
J Int Med Res; 2016 Dec; 44(6):1462-1473. PubMed ID: 28322099
[TBL] [Abstract][Full Text] [Related]
17. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition.
Granell M; Calvo X; Garcia-Guiñón A; Escoda L; Abella E; Martínez CM; Teixidó M; Gimenez MT; Senín A; Sanz P; Campoy D; Vicent A; Arenillas L; Rosiñol L; Sierra J; Bladé J; de Larrea CF;
Haematologica; 2017 Jun; 102(6):1099-1104. PubMed ID: 28255016
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Implications of Circulating Plasma Cell Percentage in Multiple Myeloma and Primary Plasma Cell Leukemia Defined by New Criteria.
Jin X; Jiang X; Li H; Shen K; Liu S; Chen M; Yang C; Han B; Zhuang J
Acta Haematol; 2024 Apr; ():1-10. PubMed ID: 38626745
[TBL] [Abstract][Full Text] [Related]
20. Exploring the Clinicopathological Parameters Affecting the Outcome in Egyptian Patients with Multiple Myeloma.
Sallam YA; Samra MA; Gaber AA
Gulf J Oncolog; 2016 Jan; 1(20):51-63. PubMed ID: 27050180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
